These results indicate that miR-21 leads to resistance to trastuzumab and chemotherapy via different mechanisms, confirming that miR-21 could serve as a comprehensive predictive marker of response to such therapy for HER2- positive breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.